Moderate-Release TAXUS(R) Express(TM) Coronary Stent System Demonstrates Sustained Long-Term Outcomes In High-Risk Patients

... Boston Scientific Corporation (NYSE: BSX) today announced three-year follow-up data from its TAXUS VI clinical trial. The data demonstrated that the safety and efficacy benefits associated with a moderate-release formulation of the TAXUS(R) Express(TM) paclitaxel-eluting stent system were maintained at three years. Analysis of the data was presented by Keith D. Dawkins, M.D. [click link for full article] ...